209335-49-9 Usage
Description
Feglymycin, an amphoteric, 13-member linear peptide, was isolated from a Streptomyces in 1999. It features 3,5-dihydroxyphenylalanine and a terminal dicarboxylate amino acid. Feglymycin is a potent antiviral agent with antibacterial activity, including against MRSA. It specifically inhibits the enzymes MurA and MurC and prevents cell-to-cell transfer between HIV-infected T cells, uninfected CD4+ T cells, and the DC-SIGN-mediated viral transfer to CD4+ T cells.
Uses
Used in Antiviral Applications:
Feglymycin is used as an antiviral agent for its potent activity against various viruses. It inhibits the enzymes MurA and MurC, which are essential for bacterial cell wall synthesis, and also prevents the transfer of HIV between infected and uninfected T cells, as well as the DC-SIGN-mediated viral transfer to CD4+ T cells.
Used in Antibacterial Applications:
Feglymycin is used as an antibacterial agent for its effectiveness against MRSA (Methicillin-resistant Staphylococcus aureus) and other bacteria. Its ability to inhibit key enzymes in bacterial cell wall synthesis makes it a valuable tool in the fight against antibiotic-resistant infections.
Used in Pharmaceutical Industry:
Feglymycin is used as a potential therapeutic agent in the pharmaceutical industry due to its antiviral and antibacterial properties. Its unique mechanism of action and effectiveness against drug-resistant strains make it a promising candidate for the development of new treatments for various infectious diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 209335-49-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,3,3 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 209335-49:
(8*2)+(7*0)+(6*9)+(5*3)+(4*3)+(3*5)+(2*4)+(1*9)=129
129 % 10 = 9
So 209335-49-9 is a valid CAS Registry Number.
209335-49-9Relevant articles and documents
Total synthesis of the antiviral peptide antibiotic feglymycin
Dettner, Frank,Haenchen, Anne,Schols, Dominique,Toti, Luigi,Nusser, Antje,Suessmuth, Roderick D.
supporting information; experimental part, p. 1856 - 1861 (2009/09/06)
An adaptable approach: The first highly convergent stereoselective synthesis of feglymycin (see structure) and its enantiomer is based on the coupling of repeating peptide fragments. The use of weakly basic conditions throughout the synthesis suppressed t
